zedie posted: " Abstract BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proli" Read on blog or Reader SOMEONE SOMEWHERE Read on blog or Reader Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis zedie February 29 Abstract BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown. METHODS In this multinational, […] Read more of this post Comment Like You can also reply to this email to leave a comment.

SOMEONE SOMEWHERE © 2024. Manage your email settings or unsubscribe. Get the Jetpack app Subscribe, bookmark, and get real-time notifications - all from one app! Automattic, Inc. - 60 29th St. #343, San Francisco, CA 94110